
❓ Struggling with #biomarker assay sensitivity? Working with novel targets or exploratory endpoints? Elizabeth Hickford from @Resolian_ explains how understanding your context of use from the very first conversation can make or break your bioanalytical strategy. Whether you're measuring low-abundance biomarkers in tissue extracts or developing assays for free vs. drug-bound targets, this interview is packed with practical guidance. Don't miss it >>> hubs.ly/Q04zg5LP0












